北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study
作者: Hu, Hao1; Duan, Zhenhua2; Long, Xiaoran3; Hertzanu, Yancu4; Tong, Xiaoqiang5; Xu, Xiaoquan6; Shi, Haibin1; Liu, Sheng1; Yang, Zhengqiang1
刊名: PLOS ONE
发表日期: 2015-02-17
DOI: 10.1371/journal.pone.0117168
卷: 10, 期:2
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Multidisciplinary Sciences
研究领域[WOS]: Science & Technology - Other Topics
关键词[WOS]: TRANS-ARTERIAL CHEMOEMBOLIZATION ; PHASE-II ; MANAGEMENT ; PROGNOSIS ; OUTCOMES
英文摘要:

Aims

This retrospective study was carried out to compare the outcomes between elderly (>= 70 years of age) and nonelderly patients (< 70 years of age) with advanced hepatocellular carcinoma (HCC) who received sorafenib combined with transarterial chemoembolization (TACE).

Methods

88 patients with a confirmed diagnosis of advanced HCC were enrolled in this study. Of these, 24 elderly patients were matched with 48 nonelderly patients at a 1:2 ratio using propensity score matching to minimize selection bias. The related adverse events and survival benefits were compared between the two groups.

Results

Sorafenib combined with TACE was equally well tolerated in both age groups, and grade 3 or 4 adverse events were similarly observed in 54.2% of elderly and 50.0% of nonelderly patients (P = 0.739). There were no significant differences in survival time between the elderly and nonelderly patients (P = 0.876). Significant prognostic factors for overall survival as identified by multivariate analysis were the Child-Pugh score and portal vein invasion.

Conclusions

Sorafenib combined with TACE may be well tolerated and effective in elderly patients with advanced HCC. Age alone is not a parameter for the treatment of advanced HCC patients.

语种: 英语
WOS记录号: WOS:000350322700029
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56293
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel
2.Chengdu Ctr Dis Control & Prevent, Chengdu, Peoples R China
3.Anhui Med Univ, Sch Pharm, Hefei, Peoples R China
4.Nanjing Med Univ, Affiliated Hosp 1, Dept Intervent Radiol, Nanjing, Jiangsu, Peoples R China
5.Peking Univ, Hosp 1, Dept Intervent Radiol & Vasc Surg, Beijing 100871, Peoples R China
6.Nanjing Med Univ, Affiliated Hosp 1, Dept Radiol, Nanjing, Jiangsu, Peoples R China

Recommended Citation:
Hu, Hao,Duan, Zhenhua,Long, Xiaoran,et al. Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study[J]. PLOS ONE,2015,10(2).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Hu, Hao]'s Articles
[Duan, Zhenhua]'s Articles
[Long, Xiaoran]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Hu, Hao]‘s Articles
[Duan, Zhenhua]‘s Articles
[Long, Xiaoran]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace